lurasidone
Nervous system (N05)Nervous system (N05) compound in Sumitomo Pharma Co's portfolio. Mechanism: Dopamine D2 receptor antagonist.
- Mechanism
- Dopamine D2 receptor antagonist
pharma · Malignant Pleural Mesothelioma · Bipolar I Depression
Sumitomo Pharma Co
Sumitomo Pharma (Suzhou) Co.,
Sumitomo Pharma Co drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
JP HQ
1897 Founded
193 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- JP
- Founded
- 1897
- Employees
- 193
- Programs
- 4
- Drugs
- 3
- Patents
- 0
Sumitomo Pharma Co pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Sumitomo Pharma Co drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Sumitomo Pharma Co in public FDA and regional records.
-
Development asset linked to Sumitomo Pharma Co in public FDA and regional records.